<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867096</url>
  </required_header>
  <id_info>
    <org_study_id>2020/482</org_study_id>
    <nct_id>NCT04867096</nct_id>
  </id_info>
  <brief_title>Supervised Exercise, Sleep in Patients With Non Metastatic Breast Cancer</brief_title>
  <acronym>FATSOMCAN</acronym>
  <official_title>Effects of a Supervised Exercise on Sleep in Patients With Non Metastatic Breast Cancer During Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insomnia affects about 60% of the patients treated with radio-chemotherapy, a percentage&#xD;
      twice higher compared to that observed in the general population. This sleep disorder&#xD;
      increases cancer-related fatigue (CRF), the side effect most often reported by patients.&#xD;
      Conversely, it is well accepted that adapted physical activity (APA) improves tolerance to&#xD;
      treatment, decreases the risk of recurrence, increases survival, and reduces CRF. The present&#xD;
      study aims to evaluate, in non-metastatic breast cancer patients, the composition and&#xD;
      architecture of sleep by ambulatory polysomnography and to verify the effects of an APA&#xD;
      rehabilitation program (3 times a week during 12 weeks), on the quality and quantity of&#xD;
      sleep, daytime sleepiness. The biological markers: melatonin and body temperature will be&#xD;
      studied to better understand the chronobiological mechanisms of the sleep-wake rhythm.&#xD;
      Finally, the physiological responses to exercise, pain, CRF and finally quality of life will&#xD;
      be studied at the beginning, at the end of the program and at a distance from it. Improved&#xD;
      sleep-wake rhythm by a physical activity may reduce CRF, prevent recurrence and&#xD;
      comorbidities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Total sleep time at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated with polysomnography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline quality of sleep at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated with actimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Score of fatigue at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated with questionnaire Multidimensional Fatigue Inventory (score between 20 to 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline body composition at 3 months</measure>
    <time_frame>3 months.</time_frame>
    <description>Evaluated bioimpedance BMI in Kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of pain</measure>
    <time_frame>Baseline (T0) , 3 months (T3).</time_frame>
    <description>Evaluated by questionnaire Brief Pain Inventory-Short Form (score between 15 to 150)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory responses</measure>
    <time_frame>Baseline (T0), 3 months (T3).</time_frame>
    <description>Evaluated with enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of physical activity</measure>
    <time_frame>Baseline (T0), 3 months (T3), 6 months (T6).</time_frame>
    <description>Evaluated with smartwatch withings with number of step</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic respiratory functional exploration</measure>
    <time_frame>Baseline (T0), 3 months (T3).</time_frame>
    <description>Evaluated by pneumotachography (Sensors Medics MSE, USA) for the evaluation of bronchial volumes and flows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of anxiety</measure>
    <time_frame>Baseline (T0), 3 months (T3), 6 months (T6).</time_frame>
    <description>Evaluated by questionnaire Hospital Anxiety and Depression scale (under 7 to more than 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Melatonin</measure>
    <time_frame>Baseline (T0), 3 months (T3), 6 months (T6).</time_frame>
    <description>Evaluated by saliva samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Baseline (T0), 3 months (T3), 6 months (T6).</time_frame>
    <description>Evaluated by thermobuttons</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Physical activity intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A : &quot;standard oncologic care coupled with physical activity intervention (3 times / week) &quot; during 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm B : &quot;standard oncologic care&quot;.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical activity</intervention_name>
    <description>Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.</description>
    <arm_group_label>Physical activity intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 to 65&#xD;
&#xD;
          -  Patients with non-metastatic breast cancer undergoing chemotherapy&#xD;
&#xD;
          -  Patients with insomnia&#xD;
&#xD;
          -  Certificate of non-contraindication to the practice of physical activity&#xD;
&#xD;
          -  Women who have been postmenopausal for at least 24 months, surgically sterilized, or,&#xD;
             for women of childbearing potential, use an effective method of contraception (oral&#xD;
             contraceptives, contraceptive injections, intrauterine devices, double-barrier method,&#xD;
             contraceptive patches)&#xD;
&#xD;
          -  Signature of informed consent to participate indicating that the subject has&#xD;
             understood the purpose and procedures required by the study and that he agrees to&#xD;
             participate in the study and to comply with the requirements and restrictions inherent&#xD;
             in this study&#xD;
&#xD;
          -  Affiliation to a French social security scheme or beneficiary of such a scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated with melatonin or taking hypnotics&#xD;
&#xD;
          -  Patients with metastases&#xD;
&#xD;
          -  Oxygen saturation at rest (SaO2) ≤ 92%&#xD;
&#xD;
          -  Patients without insomnia and / or sleep disorders&#xD;
&#xD;
          -  Autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis)&#xD;
&#xD;
          -  Symptomatic osteoarthritis, cardiovascular disease (angina pectoris or uncontrolled&#xD;
             hypertension) or lung disease (chronic obstructive pulmonary disease)&#xD;
&#xD;
          -  Patients suffering from malnutrition (BMI &lt;18 kg.m-2) or weight loss&gt; 10% during the&#xD;
             previous 3 months&#xD;
&#xD;
          -  Patients with psychiatric or cognitive disorders deemed unsuitable for physical&#xD;
             activity&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Subject unlikely to cooperate with the study and / or weak cooperation anticipated by&#xD;
             the investigator&#xD;
&#xD;
          -  Subject without health insurance&#xD;
&#xD;
          -  Subject being in the period of exclusion from another study or provided for by the&#xD;
             &quot;national file of volunteers&quot;.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MOUGIN-GUILLAUME Fabienne</last_name>
    <phone>0363082585</phone>
    <email>fabienne.mougin-guillaume@univ-fcomte.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne MOUGIN-GUILLAUME</last_name>
      <email>fabienne.mougin-guillaume@univ-fcomte.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

